Thursday, June 25, 2026
🇺🇸 FDA

Clinical Tools · Venous Thromboembolism · Pulmonary Embolism

Wells PE Score Calculator

Calculate pre-test probability of acute pulmonary embolism using the standard Wells PE criteria with weighted points. Supports two-tier and three-tier interpretation, D-dimer and imaging pathway context, and VTE anticoagulant trial endpoint guidance for pharma professionals.

Quick Answer

The Wells PE score estimates pre-test probability of acute pulmonary embolism using clinical signs, alternative diagnosis likelihood, heart rate, immobilization, prior VTE, hemoptysis, and malignancy. Two-tier interpretation classifies PE as unlikely (≤4) or likely (>4), guiding D-dimer versus CT pulmonary angiography pathways. Pharma teams use Wells PE for VTE anticoagulant trial endpoint and diagnostic algorithm literacy.

Wells PE score
Total = DVT signs + PE likely + HR>100 + Immobilization + Prior VTE + Hemoptysis + Malignancy
Weighted points (max 13.5). Two-tier: >4 likely PE, ≤4 unlikely. Three-tier: >6 high, 2–6 moderate, <2 low.

Calculate Wells PE Score

Select all criteria that apply. Each criterion adds its weighted point value to the total score.

Wells PE criteria

Pre-test probability

-

-

-

-

Total score
-
/ 13.5 points
Criteria selected
-
of 7
Two-tier
-
>4 likely / ≤4 unlikely
Three-tier
-
>6 / 2–6 / <2

How to Use the Wells PE Calculator

1
Evaluate the patient for DVT signs, hemoptysis, tachycardia, recent immobilization or surgery, prior VTE, and active malignancy.
2
Assess whether PE is the leading diagnosis versus alternative explanations (pneumonia, ACS, musculoskeletal pain).
3
Select applicable criteria and calculate the weighted total score.
4
Apply two-tier (>4 vs ≤4) and three-tier (>6 / 2–6 / <2) interpretation, then follow institutional D-dimer and imaging pathways—not as a standalone treatment decision.

Worked Example

Example calculation

Patient: 58-year-old with acute dyspnea, pleuritic chest pain, HR 112, unilateral calf swelling, no hemoptysis, no prior VTE, no recent surgery, active breast cancer on chemotherapy.

Criteria met: DVT signs (+3.0), PE #1 diagnosis (+3.0), HR >100 (+1.5), malignancy (+1.0).

Total Wells PE: 8.5 points — two-tier: likely PE (>4); three-tier: high probability (>6). Proceed to imaging (CTPA); D-dimer alone insufficient. Anticoagulation per protocol pending confirmation.

Two-Tier and Three-Tier Interpretation

Low / unlikely (two-tier ≤4) Three-tier: <2 low; 2–6 moderate

Negative high-sensitivity D-dimer may exclude PE without imaging in low-probability pathways. Moderate tier often requires D-dimer with imaging if positive.

Likely / high (two-tier >4) Three-tier: >6 high

Proceed to CTPA or V/Q scan. D-dimer lacks adequate negative predictive value. Empiric anticoagulation may apply per emergency protocol pending imaging.

D-Dimer and Imaging Pathways

Wells PE stratifies pre-test probability to select the next diagnostic step. In low-probability patients (two-tier ≤4 with score <2, or moderate 2–6 per local rules), a negative high-sensitivity D-dimer can rule out PE. Age-adjusted D-dimer (age × 10 µg/L FEU in patients ≥50) reduces false-positive imaging in older populations.

High pre-test probability (>4 two-tier; >6 three-tier) warrants direct imaging—CT pulmonary angiography is first-line in most centers; V/Q scan when contrast contraindicated. Wells score does not replace imaging for diagnosis or define anticoagulant trial eligibility.

For complementary lower-extremity assessment, see our Wells DVT Score Calculator. For bleeding risk once anticoagulation is initiated, use our HAS-BLED Score Calculator.

VTE Anticoagulant Trial Endpoints for Pharma Professionals

Phase 3 VTE trials (EINSTEIN, AMPLIFY, Hokusai-VTE) enroll objectively confirmed DVT or PE and report recurrent VTE, fatal PE, and major bleeding as primary or key secondary endpoints. Wells PE may appear in screening documentation, registry baseline characteristics, or health-economic models estimating diagnostic costs before therapeutic enrollment.

Extended anticoagulation trials (EINSTEIN CHOICE, AMPLIFY-EXT) focus on confirmed index events—not Wells-score triage. Medical affairs teams should distinguish pre-test probability tools (Wells) from trial inclusion criteria (objective VTE confirmation) and adjudicated efficacy/safety endpoints.

Subpopulation analyses may stratify outcomes by cancer-associated thrombosis (Wells malignancy criterion) or prior VTE history. Baseline Wells distribution helps contextualize real-world diagnostic pathways that precede anticoagulant initiation in market-access and medical education materials.

Thrombolytic Trial Context

Thrombolysis trials in submassive or massive PE (PEITHO, TOPCOAT) enroll hemodynamically or echocardiographically defined populations—not Wells-score thresholds. Wells PE supports emergency triage before eligibility assessment; trial endpoints include mortality, hemodynamic decompensation, recurrent PE, major bleeding, and intracranial hemorrhage.

Sponsors developing thrombolytic or anticoagulant assets for PE should document that Wells guides diagnostic probability, while trial protocols specify objective enrollment criteria and adjudicated outcomes independent of pre-test scores.

Limitations and Caveats

The subjective “PE is #1 diagnosis” criterion introduces inter-observer variability. Wells PE does not incorporate troponin, BNP, echocardiographic RV strain, or CT findings. Performance varies with prevalence and D-dimer assay characteristics.

Do not delay imaging or resuscitation in unstable patients with high clinical suspicion regardless of score. Wells PE estimates probability—it does not diagnose PE, select anticoagulant dose, or replace institutional VTE pathways.

For acute coronary syndrome triage in patients with chest pain and dyspnea, see our HEART Score Calculator. For stroke-risk assessment in atrial fibrillation patients who may also have VTE risk factors, see our CHA₂DS₂-VASc Score Calculator.

Interpretation Reference Table

Wells PE score Two-tier Three-tier Typical next step
<2 Unlikely (≤4) Low High-sensitivity D-dimer; imaging if positive
2 – 4 Unlikely (≤4) Moderate D-dimer; imaging if positive or per pathway
4.5 – 6 Likely (>4) Moderate Imaging (CTPA/V/Q); D-dimer insufficient to exclude
>6 Likely (>4) High Direct imaging; consider empiric anticoagulation per protocol

Evidence & Sources

Frequently Asked Questions

The Wells PE score (Wells criteria for PE) estimates the pre-test probability of acute pulmonary embolism using seven clinical variables with weighted points. It is widely used in emergency and inpatient pathways to decide whether D-dimer testing, imaging, or empiric anticoagulation is appropriate before CT pulmonary angiography (CTPA) or V/Q scan.
Assign points for each present criterion: clinical signs/symptoms of DVT (+3.0), alternative diagnosis less likely than PE (+3.0), heart rate >100 bpm (+1.5), immobilization ≥3 days or surgery in prior 4 weeks (+1.5), previous objectively diagnosed PE or DVT (+1.5), hemoptysis (+1.0), and malignancy with treatment within 6 months or palliative care (+1.0). Sum the points for the total score (maximum 13.5).
In the two-tier (simplified) model, a score >4 indicates PE is likely and generally warrants imaging (CTPA or V/Q scan) rather than D-dimer alone. A score ≤4 indicates PE is unlikely; if pre-test probability is low, a negative high-sensitivity D-dimer may exclude PE without immediate imaging per many institutional pathways.
The three-tier model stratifies pre-test probability as low (<2 points), moderate (2–6 points), and high (>6 points). Low probability patients may proceed to D-dimer; moderate probability often requires D-dimer with imaging if positive; high probability typically warrants direct imaging and may support empiric anticoagulation pending confirmation per local protocol.
Wells PE and Wells DVT are related but distinct instruments. The PE score emphasizes PE-specific features (PE as leading diagnosis, hemoptysis) and shares DVT signs, immobilization, prior VTE, and malignancy. The DVT score uses different criteria and cutoffs for lower-extremity deep vein thrombosis probability. Use the PE score when evaluating suspected pulmonary embolism, not isolated leg symptoms alone.
In low or moderate pre-test probability (two-tier ≤4; three-tier <2 or 2–6 with pathway-specific rules), a negative high-sensitivity D-dimer can exclude PE without imaging. In high pre-test probability (>4 two-tier; >6 three-tier), D-dimer lacks sufficient negative predictive value—proceed to CTPA or V/Q scan. Age-adjusted D-dimer thresholds apply in patients ≥50 years in many guidelines.
Phase 3 VTE trials (DVT, PE, extended treatment) enroll patients with objectively confirmed events; Wells PE may appear in screening logs, registry baseline data, or health-economic models estimating diagnostic pathway costs. Trial protocols define efficacy endpoints (recurrent VTE, fatal PE) and safety endpoints (major bleeding, CRNMB) independently of Wells score, but pre-test probability tools inform real-world treatment pathways that trials seek to improve.
Massive and submassive PE trials (thrombolysis vs anticoagulation alone) enroll hemodynamically defined populations, not Wells-score-defined cohorts. Wells PE helps emergency triage before enrollment decisions. Trial endpoints— mortality, hemodynamic collapse, right ventricular dysfunction, bleeding—are adjudicated separately. Medical affairs teams may reference Wells context when explaining diagnostic pathways preceding thrombolytic eligibility.
No. Wells PE estimates pre-test probability; it does not diagnose or exclude PE. Definitive diagnosis requires imaging (CTPA, V/Q scan) or, in select low-probability patients, validated D-dimer exclusion algorithms. Anticoagulation initiation without confirmation follows institutional protocols and may apply only in high-probability emergencies pending imaging.
Wells PE performance depends on prevalence, D-dimer assay, and age-adjusted thresholds. Subjective criteria ("PE is #1 diagnosis") introduce inter-observer variability. The score does not incorporate biomarkers (troponin, BNP), RV strain on echo, or CT findings. It should not delay imaging in unstable patients with high clinical suspicion regardless of score.
YEARS, revised Geneva, and Wells PE are alternative pre-test probability models for suspected PE. Institutional preference varies; some pathways use Wells two-tier with D-dimer, others use YEARS or age-adjusted strategies. No single score is universally superior—validation cohorts and local D-dimer performance should guide protocol selection in clinical programs.
No. Wells PE supports diagnostic probability assessment, not anticoagulant dose selection. DOAC and parenteral anticoagulant dosing follows approved labels (indication, renal function, body weight, bleeding risk). HAS-BLED and other bleeding scores may complement VTE management when long-term anticoagulation is initiated after confirmed PE.

Related Tools

WDVT Wells DVT Score HB HAS-BLED Score C2V CHA₂DS₂-VASc Score HEART HEART Score

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.